1605P Number of untimely deaths prevented with ALK-inhibitors in Brazilian patients with advanced non-small cell lung cancer with ALK driver mutations

Abstract

Conclusions: Our pupulation-based analysis confirms that first line pazopanib and sunitinib have comparable DT and OS, although cost of sunitinib without managed entry agreements is higher. Nivolumab and cabozantinib have superior DT both in second and third line setting, with nivolumab being the most expensive drug.Legal entity responsible for the study: The authors.Funding: IPSEN.